ArticleACS nano2025
A Modular Supramolecular Peptide Platform Reveals Atomic-Number-Dependent Mechanisms Driving Radioenhancement.
Article in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimizing radioenhancer design for cancer therapy has been limited by inconsistent metal comparisons and unclear nanoscale mechanisms. High-Z nanoparticles are expected to enhance radiation effects through increased photoelectric absorption and secondary electron production, with the common assumption that radioenhancement efficacy increases uniformly with atomic number. However, this linear relationship may be oversimplified. Here, we introduce a versatile, supramolecular peptide platform enabling direct and standardized comparison of gadolinium (Gd), bismuth (Bi), and hafnium (Hf) as radioenhancers within a single, biologically targeted framework. This system is based on autoassembled peptide heterodimers (E3-K3) incorporating a flexible chelator (DOTAGA) and variable heavy-chain antibody (VHH) domains, ensuring uniform cellular uptake and precise tumor targeting. Systematic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.